The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Molecular targets for breast cancer therapy and prevention
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Self-citationSlamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Greenlee, R. T., Murray, T., Bolden, S., & Wingo, P. A. (2000) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.50.1.7 · Cited by 3,850
Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., et al. (1984) · Nature · doi:10.1038/309418a0 · Cited by 2,752
Self-citationCoussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,814
Self-citationAntiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683
ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics
McPherson, K. (2000) · BMJ · doi:10.1136/bmj.321.7261.624 · Cited by 1,570
Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
Millauer, B., Shawver, L. K., Plate, K. H., Risaui, W., & Ullrich, A. (1994) · Nature · doi:10.1038/367576a0 · Cited by 1,221
Self-citationRichon, V. M., Sandhoff, T. W., Rifkind, R. A., & Marks, P. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180316197 · Cited by 1,090
Fong, T. A. T., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T., Kim, Y. H., Schreck, R., Wang, X., Risau, W., et al. (1999) · PubMed · Cited by 1,026
Self-citationTumor angiogenesis: past, present and the near future
Kerbel, R. S. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.505 · Cited by 976
The biology of erbB-2/nue/HER-2 and its role in cancer
Hynes, N. (1994) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(94)90012-4 · Cited by 971
Ciardiello, F., Caputo, R., Bianco, R., Damiano, Pomatico, G., De Placido, S., Bianco, A. R., & Tortora, G. (2000) · PubMed · Cited by 943
Gusterson, B. A., Gelber, R. D., Goldhirsch, A., Price, K. N., Säve-Söderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C. M., Golouh, R., & Reed, R. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1049 · Cited by 838
Annual hazard rates of recurrence for breast cancer after primary therapy.
Saphner, T., Tormey, D. C., & Gray, R. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2738 · Cited by 830
Weighing the Risks and Benefits of Tamoxifen Treatment for Preventing Breast Cancer
Gail, M. H., Costantino, J. P., Bryant, J., Croyle, R., Freedman, L., Helzlsouer, K., & Vogel, V. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.21.1829 · Cited by 670
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski, M. X., Ja, L., Gd, L., Te, H., FENDLY, B. M., & Fox, J. A. (1999) · PubMed · Cited by 653
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
Harari, D., & Yarden, Y. (2000) · Oncogene · doi:10.1038/sj.onc.1203973 · Cited by 633
Mutations truncating the EP300 acetylase in human cancers
Gayther, S. A., Batley, S. J., Linger, L., Bannister, A., Thorpe, K., Chin, S.-F., Daigo, Y., Russell, P., Wilson, A., Sowter, H. M., et al. (2000) · Nature Genetics · doi:10.1038/73536 · Cited by 587
Fossati, R., Confalonieri, C., Torri, V, Ghislandi, E., Penna, A., Pistotti, V, Tinazzi, A., & Liberati, A. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3439 · Cited by 546
Combinatorial chemoprevention of intestinal neoplasia
Torrance, C. J., Jackson, P. E., Montgomery, E., Kinzler, K. W., Vogelstein, B., Wissner, A., Nunes, M., Frost, P., & Discafani, C. M. (2000) · Nature Medicine · doi:10.1038/79534 · Cited by 493
The mammary gland iodide transporter is expressed during lactation and in breast cancer
Tazebay, U. H., Wapnir, I. L., Levy, O., Dohan, O., Zuckier, L. S., Hua Zhao, Q., Fu Deng, H., Amenta, P. S., Fineberg, S., Pestell, R. G., et al. (2000) · Nature Medicine · doi:10.1038/78630 · Cited by 493
Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators
Senderowicz, A. M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.5.376 · Cited by 492
Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor.
Harris, R. E., Alshafie, G. A., Abou‐Issa, H., & Seibert, K. (2000) · PubMed · Cited by 486
Wright, C., Nicholson, S., Angus, B., Sainsbury, J., Farndon, J., Cairns, J., Harris, A., & Horne, C. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.22 · Cited by 379
Pestell, R. G., Albanese, C., Reutens, A. T., Segall, J. E., Lee, R. J., & Arnold, A. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.4.0373 · Cited by 375
Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor
Mazumdar, A., Wang, R.-A., Mishra, S. K., Adam, L., Bagheri-Yarmand, R., Mandal, M., Vadlamudi, R. K., & Kumar, R. (2001) · Nature Cell Biology · doi:10.1038/35050532 · Cited by 364
Kurokawa, H., Lenferink, A. E. G., Simpson, J. F., Pisacane, P. I., Sliwkowski, M. X., Forbes, J. T., & Arteaga, C. L. (2000) · PubMed · Cited by 363
Lee, R. J., Albanese, C., Fu, M., D'Amico, M., Lin, B., Watanabe, G., Haines, G. K., Siegel, P. M., Hung, M.-C., Yarden, Y., et al. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.2.672-683.2000 · Cited by 347
Sjögren, S., Inganäs, M., Lindgren, A., Holmberg, L., & Bergh, J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.462 · Cited by 327
Pietras, R. J., Poen, J. C., Gallardo, D., Wongvipat, P. N., Lee, H. J., & Slamon, D. J. (1999) · PubMed · Cited by 311
High constant incidence in twins and other relatives of women with breast cancer
Peto, J., & Mack, T. M. (2000) · Nature Genetics · doi:10.1038/82533 · Cited by 301
Dixon, J. M. (2012) · Medical Entomology and Zoology · Cited by 287
Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis
Saaristo, A., Karpanen, T., & Alitalo, K. (2000) · Oncogene · doi:10.1038/sj.onc.1203969 · Cited by 264
Borg, Å., Baldetorp, B., Fernö, M., Killander, D., Olsson, H., Ryden, S., & Sigurdsson, H. (1994) · Cancer Letters · doi:10.1016/0304-3835(94)90194-5 · Cited by 246
Yang, X., Ferguson, A. T., Nass, S. J., Phillips, D. L., Butash, K. A., Wang, S. M., Herman, J. G., & Davidson, N. E. (2000) · PubMed · Cited by 228
Clinical trials of Herceptin® (trastuzumab)
Baselga, J. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00404-4 · Cited by 227
Regulation of Cyclooxygenase-2 pathway by HER2 receptor
Vadlamudi, R., Mandal, M., Adam, L., Steinbach, G., Mendelsohn, J., & Kumar, R. (1999) · Oncogene · doi:10.1038/sj.onc.1202307 · Cited by 222
Houston, S. J., Plunkett, T. A., Barnes, D. M., Smith, P., Rubens, R. D., & Miles, D. W. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690196 · Cited by 220
Oxidative Stress and AP-1 Activity in Tamoxifen-Resistant Breast Tumors In Vivo
Schiff, R. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.23.1926 · Cited by 211
Nicholson, R. I., McClelland, R. A., Gee, J. M. W., Manning, D. L., Cannon, P., Robertson, J. F. R., Ellis, I. O., & Blamey, R. W. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00666187 · Cited by 190
Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment
Berns, E. M. J. J., Foekens, J. A., van Staveren, I. L., van Putten, W. L. J., de Koning, H. Y. W. C. M., Portengen, H., & Klijn, J. G. M. (1995) · Gene · doi:10.1016/0378-1119(94)00534-y · Cited by 173
p53-independent apoptosis induced by paclitaxel through an indirect mechanism
Lanni, J. S., Lowe, S. W., Licitra, E. J., Liu, J. O., & Jacks, T. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.18.9679 · Cited by 172
The Ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis
Xing, X., Wang, S.-C., Xia, W., Zou, Y., Shao, R., Kwong, K. Y., Yu, Z., Zhang, S., Miller, S., Huang, L., et al. (2000) · Nature Medicine · doi:10.1038/72294 · Cited by 164
Suberoylanilide Hydroxamic Acid as a Potential Therapeutic Agent for Human Breast Cancer Treatment
Huang, L., & Pardee, A. B. (2000) · Molecular Medicine · doi:10.1007/bf03401823 · Cited by 164
Archer, S., Eliopoulos, A., Spandidos, D., Barnes, D., Ellis, I., Blamey, R., Nicholson, R., & Robertson, J. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.497 · Cited by 159
Inhibition of CDKs as a Therapeutic Modality
Sausville, E. A., Johnson, J. I., Alley, M. C., Zaharevitz, D. W., & Senderowicz, A. M. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06710.x · Cited by 80
Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression.
Jacquemier, J. D., Penault-Llorca, F. M., Viens, P., Houvenaeghel, G. F., Hassoun, J., Torrente, M., Adélaı̈de, J., & Birnbaum, D. (1994) · PubMed · Cited by 44
Role of Retinoid Receptors in the Prevention and Treatment of Breast Cancer
Yang, L., Tin-U, C., Wu, K., & Brown, P. H. (1999) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1018718401126 · Cited by 39
Fenretinide and cancer prevention
Torrisi, R., & DeCensi, A. (2000) · Current Oncology Reports · doi:10.1007/s11912-000-0077-x · Cited by 28
Cited by
Bissell, M. J., & Radisky, D. (2001) · Nature Reviews Cancer · doi:10.1038/35094059 · Cited by 2,180
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858
“Numerous efforts have been directed at devel-As the only FDA-approved therapeutic antibody for meta-oping ErbB2-targeting cancer therapies (Bange et al., 2001). static breast cancer, trastuzumab has demonstrated durable One successful example is the recombinant humanized anti-responses as a single…”
BackgroundInsulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 882
Histone deacetylase inhibitors as new cancer drugs
Marks, P. A., Richon, V. M., Breslow, R., & Rifkind, R. A. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200111000-00010 · Cited by 531
Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy
Özcelik, C., Erdmann, B., Pilz, B., Wettschureck, N., Britsch, S., Hübner, N., Chien, K. R., Birchmeier, C., & Garratt, A. N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122249299 · Cited by 473
Metadata
- Authors
- Bange, J., Zwick, E., & Ullrich, A.
- Venue
- Nature Medicine
- Published
- 2001-05
- Volume
- 7
- Issue
- 5
- Pages
- 548-552
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1849061857
- Cited by
- 288
- References
- 53
- FWCI
- 7.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.